Human Reproduction, Vol. 17, No. 11, 2807-2812,
November 2002
© 2002 European Society of Human Reproduction and Embryology
Preimplantation genetic diagnosis for fragile Xa syndrome: difficult but not impossible
1 Centres for Reproductive Medicine and 2 Medical Genetics, University Hospital and Medical school, Dutch-speaking Brussels Free University, Laarbeeklaan 101, 1090 Brussels, Belgium
BACKGROUND: In this paper, we review our clinical preimplantation genetic diagnosis (PGD) programme for fragile Xa syndrome, analysing if PGD for these couples is still a valuable option, as it is particularly difficult for two reasons. First, the couples have to be informative (the number of triplet repeats on the healthy FMR-1 allele of the mother has to be different from the number of repeats on the healthy FMR-1 allele of the father) and second, women with a premutation are at increased risk of premature ovarian failure. METHODS: A total of 34 couples attended our genetics department between December 1998 and July 2001, requesting information about PGD for fragile Xa syndrome. RESULTS: Eight couples decided not to go further with the procedure and of the 26 remaining couples, 16 were informative (61.5%). Four couples have so far not started ovarian stimulation, one patient was totally refractive to stimulation and 11 couples have had a total of 19 oocyte retrievals. From these, there have been 13 embryo transfers with a clinical pregnancy rate per embryo transfer of 23%; the implantation rate was 13.6% and the live birth rate per couple was 27.3%. CONCLUSIONS: PGD for fragile Xa is feasible for a number of couples. A pre-PGD work-up should include a determination of the premutation or mutation carrier status, the maternal or paternal origin of the premutation and an estimation of the ovarian reserve of the patient. Fragile Xa premutation carriers should be advised not to postpone reproduction for too long.
Key words: controlled ovarian stimulation/fragile X syndrome/preimplantation genetic diagnosis/premature ovarian failure/premutation
3 To whom correspondence should be addressed. E-mail: peter.platteau{at}az.vub.ac.be
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. M. Nelson Primary Ovarian Insufficiency N. Engl. J. Med., February 5, 2009; 360(6): 606 - 614. [Full Text] [PDF] |
||||
![]() |
P. Burlet, N. Frydman, N. Gigarel, V. Kerbrat, G. Tachdjian, E. Feyereisen, J.-P. Bonnefont, R. Frydman, A. Munnich, and J. Steffann Multiple displacement amplification improves PGD for fragile X syndrome Mol. Hum. Reprod., October 1, 2006; 12(10): 647 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Stouffs, W. Lissens, H. Tournaye, A. Van Steirteghem, and I. Liebaers The choice and outcome of the fertility treatment of 38 couples in whom the male partner has a Yq microdeletion Hum. Reprod., July 1, 2005; 20(7): 1887 - 1896. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Spits, M. De Rycke, N. Van Ranst, H. Joris, W. Verpoest, W. Lissens, P. Devroey, A. Van Steirteghem, I. Liebaers, and K. Sermon Preimplantation genetic diagnosis for neurofibromatosis type 1 Mol. Hum. Reprod., May 1, 2005; 11(5): 381 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. De Rycke, I. Georgiou, K. Sermon, W. Lissens, P. Henderix, H. Joris, P. Platteau, A. Van Steirteghem, and I. Liebaers PGD for autosomal dominant polycystic kidney disease type 1 Mol. Hum. Reprod., January 1, 2005; 11(1): 65 - 71. [Abstract] [Full Text] [PDF] |
||||


